Rafael Alfonso-Cristancho

TL;DR: Mepolizumab, an anti-IL-5 monoclonal antibody, is a precision therapy for eosinophilic severe asthma as discussed by the authors , which has been shown to improve the severity of severe asthma.

TL;DR: In this article , the authors compared real-world outcomes in patients receiving mepolizumab stratified by baseline maintenance oral corticosteroids (mOCS) use.

TL;DR: The strengths and limitations of available value assessment frameworks (VAF) in Latin America are assessed in this article using a taxonomy previously developed, using a systematic review of peer-reviewed journals, gray literature review, and surveys to ISPOR Latin America Industry Committee members.

TL;DR: RealITI-A as discussed by the authors was a 2-year prospective, observational study enrolling patients with severe asthma, newly prescribed mepolizumab 100mg SC and found that after 2 years, CSEs reduced by 74% and exacerbations requiring hospitalisation/ED visits reduced by 79% vs pre-treatment, while median mOCS dose reduced by 100% vs baseline.